Legislation & Regulation

On June 13, AMCP joined 24 patient and provider organizations in applauding the Supreme Court's unanimous ruling reversing the Fifth Circuit's decision in Alliance for Hippocratic Medicine et al. v FDA et al. AMCP and the undersigned organizations unequivocally support FDA's role in safeguarding patients, which has yielded approval of tens of thousands of crucial medications and devices for generations of Americans.

On May 29, AMCP released the following statement, which expresses concerns about the Illinois General Assembly's Healthcare protection Act (HB 5395). Passed on May 25, the bill restricts managed care pharmacists' ability to manage prescription drug benefits for millions of Illinoisans covered under the state’s Medicaid program, state employee group insurance, and fully insured commercial plans.

Access the AMCP Legislative Days 2024 Education Slides, to learn the terminology most associated with a Member of Congress and understand key advocacy vocabulary to help explain AMCP’s positions on the the Access to Prescription Digital Therapeutics Act of 2023 (S. 723/H.R. 1458) and the Medicaid VBPs for Patients (MVP) Act  (H.R. 2666).

On Feb. 29, 2024, the Centers for Medicare and Medicaid Services (CMS) issued The Medicare Advantage and Prescription Drug Programs: Part C and Part D Medicare Prescription Payment Plan Model Documents. AMCP submitted comments in response to this Model Documents on April 29, 2024.